Top 5 Papers
#1
Source: Nature Medicine | Authors: First author et al.
Score: 9.5/10 — Nature Medicine Phase II; 59% ORR and 12.9-month PFS with dual checkpoint blockade; clinically meaningful advance
This Phase II trial evaluated dual checkpoint inhibition combining domvanalimab (anti-TIGIT) and zimberelimab (anti-PD-1) plus FOLFOX in previously untreated advanced gastric, GEJ, and esophageal cancers. The combination achieved a confirmed objective response rate of 59% with a median PFS of 12.9 months — results that meaningfully exceed historical benchmarks for single-agent PD-1 inhibition. This trial validates the TIGIT+PD-1 dual blockade strategy in upper GI malignancies and may pave the way for a Phase III study in this setting.
Post angle: Beyond single-agent immunotherapy: dual TIGIT + PD-1 blockade with domvanalimab/zimberelimab achieves 59% ORR and 12.9-month PFS in advanced gastric/GEJ cancer (Nature Medicine). A compelling signal for next-generation checkpoint combinations. #GastricCancer #TIGIT #Immunotherapy #GIOncology
#2
Source: Nature Medicine | Authors: First author et al.
Score: 9.0/10 — Nature Medicine; transformative AI diagnostic tool; paradigm shift in early gastric cancer detection
GRAPE (Gastric Cancer Risk Assessment with AI) is a deep learning model that identifies gastric cancer from routine non-contrast CT scans with high accuracy across multiple validation cohorts. This approach leverages imaging that is already widely performed — avoiding the need for dedicated screening protocols. If validated prospectively, GRAPE could shift the paradigm toward earlier-stage gastric cancer diagnosis at population scale, particularly in high-incidence regions where endoscopy resources are limited.
Post angle: AI reads routine CT scans to detect gastric cancer before symptoms appear. GRAPE (Nature Medicine) could transform mass screening — no dedicated endoscopy required. Early detection at scale. #AI #GastricCancer #EarlyDetection #DigitalOncology
#3
Source: New England Journal of Medicine | Authors: First author et al.
Score: 9.0/10 — NEJM Phase I/II; first-in-class KRAS G12D degrader; directly targets mutation in ~40% of pancreatic cancers
Setidegrasib (ASP3082) is the first protein degrader targeting the KRAS G12D variant, which drives approximately 40% of pancreatic ductal adenocarcinomas. By forming a ternary complex between KRAS G12D and a VHL E3 ligase, the drug tags the oncogene for proteasomal degradation — a fundamentally different mechanism from KRAS inhibitors. Phase I/II results published in NEJM demonstrate antitumor activity with a manageable safety profile in a heavily pretreated population, opening a new chapter for molecularly targeted therapy in PDAC.
Post angle: The 'undruggable' is now druggable: setidegrasib degrades KRAS G12D protein in pancreatic cancer (NEJM). ~40% of PDAC patients carry this mutation. A new era for targeted therapy in one of our hardest-to-treat cancers. #PancreaticCancer #KRAS #TargetedTherapy #GIOncology
#4
Source: New England Journal of Medicine | Authors: First author et al.
Score: 8.5/10 — NEJM Phase III; evaluates intensified perioperative strategy; practice-relevant for resectable disease
The TOPGEAR Phase III trial assessed preoperative chemoradiotherapy as part of an intensified perioperative strategy for resectable gastric cancer, comparing it against perioperative chemotherapy alone. The trial reflects the evolving shift toward more aggressive multimodal treatment optimization in the curative setting. Results provide important data on the role of adding radiation to perioperative systemic therapy, with implications for treatment selection in patients with resectable disease.
Post angle: TOPGEAR (NEJM): does adding preoperative chemoradiotherapy to perioperative chemo improve outcomes in resectable gastric cancer? Important Phase III data for our daily practice decisions in the curative setting. #GastricCancer #Perioperative #GIOncology #ClinicalTrials
#5
Source: PubMed / Phase III Secondary Analysis | Authors: First author et al.
Score: 8.0/10 — Phase III RCT secondary analysis; ctDNA as dynamic biomarker for ICI response in mCRC; high clinical utility
This secondary analysis of the SAMCO-PRODIGE 54 Phase III trial evaluated early circulating tumor DNA (ctDNA) clearance as a predictor of survival in metastatic colorectal cancer patients receiving immune checkpoint inhibitors. Early ctDNA assessment emerged as a dynamic biomarker that can risk-stratify patients and guide treatment monitoring in the immunotherapy era. These findings reinforce the clinical value of liquid biopsy and support integration of ctDNA into routine mCRC management alongside genomic profiling.
Post angle: Liquid biopsy predicts who benefits from immunotherapy in mCRC: early ctDNA clearance tracks ICI response in SAMCO-PRODIGE 54. Real-time biomarker-guided decision making is becoming standard. #ColorectalCancer #ctDNA #LiquidBiopsy #Immunotherapy
Additional Papers of Interest
-
PubMed — Phase III RCT — 113-month follow-up confirms noninferiority of 3-month regimen (82.4% 5-year OS both arms) with less toxicity.
-
PubMed — Phase III RCT — Randomized trial of radiofrequency ablation plus chemotherapy vs chemotherapy alone in nonprogressive LAPC.
-
PubMed — Biomarker Study — CLDN18.2 overexpression in gastric, GEJ, and pancreatic tumors — emerging target for imaging and therapeutic strategies.
-
PubMed — Review — 2026 review on organ preservation as a therapeutic goal via effective systemic therapy, imaging, and endoscopic advances.
-
PubMed — Review — Current landscape of systemic treatment for advanced biliary tract malignancies including immunotherapy and targeted agents.
Back to all digests